Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Search
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Taking Cancer On: The Podcast
From early stage discovery to clinical trials and approval, we’re Taking Cancer On.
Podcast: Journeys through pulmonary fibrosis
As we speak to the courageous pulmonary fibrosis community, we hear heart-warming stories of determination, resilience and spirit.
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Patient centricity and site centricity in clinical trials
We are partnering with patients, caregivers and trial site staff to design and conduct our clinical trials, to provide a better experience for all.
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Cooperation with Google Quantum AI
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
Questions and Answers
Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
Experiences of living with cancer
We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Sustainable medicines that help minimize environmental impact
How we collaborate with renowned experts to lead the way in reducing solvent waste, as part of our efforts to embed sustainability into our core business.
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction